Clinical Trial Updates Due at Angiogenesis Meeting
Investigators will present a host of updates on clinical trials in retina at Angiogenesis, Exudation and Degeneration 2018 on Saturday, February 10, in Miami. Bascom Palmer Eye Institute at the University of Miami is host. Among the clinical trials that presenters will discuss: one-year data from the Proxima A trial of geographic atrophy with no intervention; initial results of a Phase Ib trial of HMR59 gene therapy (Hemera Biosciences) for dry age-related macular degeneration (AMD); a Phase I/II study of carotuximab (DE-122, Tracon Pharmaceuticals), an endoglin antibody, for refractory wet AMD; top-line Phase III results of brolucizumab (Novartis) anti-VEGF treatment for retinal disease; and the BOULEVARD Phase II trial of the anti-VEGF/anti-angiopoietin bispecific antibody RG7716 (Roche) for treatment of diabetic macular edema.
Roche ‘Virtual Pipeline’ Event
Roche will also hold a virtual pipeline event Tuesday, February 13, in which Sascha Fauser, MD, head pRED ophthalmology, will discuss the BOULEVARD Phase II trial. Jason Ehrlich, MD, PhD, senior group medical director, ophthalmology, will also present an ophthalmology overview.
Allergan at Leerink Partners Conference
Allergan has a busy month ahead. First, the company is set to report its 2017 results on Tuesday, February 6. Then on Thursday, February 15, two Allergan executives – chief commercial officer William Meury and chief R&D officer David Nicholson – will present at the Leerink Partners Seventh Annual Global Healthcare Conference in New York. The presentation will be webcast live and can be accessed at Allergan’s investor relations page or at http://wsw.com/webcast/leerink30/agn/.
Big Month for Earnings Reports
February will be a big month for other earnings reports. pSivida Corp. will report results for its second quarter of fiscal year 2018 on Wednesday, February 7. Management will host a conference call to review the results at 4:30 p.m. EST on the same day. A link to the live webcast will be available on the company’s website.
And, as its stock traded at a one-year low, Regeneron Pharmaceuticals is slated to report earnings on Thursday, February 8. The company will host a conference call and simultaneous webcast at 8:30 a.m. EST that day. A link to the conference call will be available on the company’s website.